Please enable JavaScript to continue using this application.

Compare $ALXO vs $ORGO | Chartloom

Compare

$ALXO vs $ORGO

ALX Oncology Holdings Inc · Organogenesis Holdings Inc

ALXO

ALX Oncology Holdings Inc

ORGO

Organogenesis Holdings Inc

Compare $ALXO vs $ORGO

Comparing ALX Oncology Holdings Inc and Organogenesis Holdings Inc

ALXOALX Oncology Holdings Inc

ORGOOrganogenesis Holdings Inc

ALXOALX Oncology Holdings Inc

Market cap

$168M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

8.7%

52W performance

-36.5%

FCF yield

-42.2%

ORGOOrganogenesis Holdings Inc

Market cap

$166M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.74x

Rev growth (TTM)

6.5%

YTD performance

-72.2%

52W performance

-68.8%

FCF yield

12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ALXO

ORGO

Detailed metrics comparison

ALXO

ALX Oncology Holdings Inc

ORGO

Organogenesis Holdings Inc

Market Cap

ALXO$168M

ORGO$166M

Enterprise Value

ALXO$156M

ORGO$132M

Price

ALXO$1.25

ORGO$1.29

P/E Ratio

ALXON/A

ORGON/A

P/S Ratio

ALXO46.09x

ORGO0.36x

EV/Sales

ALXO0.00x

ORGO0.29x

EV/EBITDA

ALXO0.00x

ORGO7.37x

P/B Ratio

ALXO1.24x

ORGO0.59x

P/FCF Ratio

ALXON/A

ORGO7.96x

EV/FCF

ALXO-2.20x

ORGO6.31x

PEG Ratio

ALXON/A

ORGON/A

Forward P/E (NTM)

ALXON/A

ORGON/A

Forward P/S (NTM)

ALXON/A

ORGO0.74x

Revenue (TTM)

ALXO$0

ORGO$457M

Revenue Growth (YoY)

ALXON/A

ORGO6.5%

Forward Rev Growth

ALXO357.6%

ORGO37.6%

Gross Margin (TTM)

ALXO9.0%

ORGO70.4%

Operating Margin (TTM)

ALXO0.0%

ORGO0.0%

EBITDA Margin (TTM)

ALXO0.0%

ORGO-2.0%

Net Margin (TTM)

ALXO0.0%

ORGO-23.1%

FCF Margin (TTM)

ALXON/A

ORGO4.6%

Net Income (TTM)

ALXO$-81M

ORGO$-106M

FCF (TTM)

ALXO$-71M

ORGO$21M

EPS (TTM)

ALXO-$0.60

ORGO-$0.82

ROE (TTM)

ALXO-9030.0%

ORGO-2260.0%

ROA (TTM)

ALXO-6728.0%

ORGO-1654.0%

ROIC (TTM)

ALXO-8046.0%

ORGO-2187.0%

Cash

ALXO$23M

ORGO$46M

Debt

ALXO$11M

ORGO$12M

Net Cash/Debt

ALXO$12M

ORGO$34M

Current Ratio (TTM)

ALXO9.71x

ORGO3.52x

Quick Ratio (TTM)

ALXO9.44x

ORGO2.66x

Debt/Equity (TTM)

ALXO0.08x

ORGO0.04x

Debt/Assets (TTM)

ALXO0.0%

ORGO0.0%

Interest Coverage (TTM)

ALXON/A

ORGON/A

Net Debt/EBITDA (TTM)

ALXO0.00x

ORGO0.00x

Beta

ALXO0.55

ORGO1.44

52W Performance

ALXO-36.5%

ORGO-68.8%

YTD Performance

ALXO8.7%

ORGO-72.2%

% from 52W High

ALXO-53.0%

ORGO-81.8%

% from 52W Low

ALXO19.0%

ORGO3.2%

Asset Turnover (TTM)

ALXO0.00x

ORGO0.90x

FCF Yield (TTM)

ALXO-42.2%

ORGO12.6%

Earnings Yield (TTM)

ALXO-48.1%

ORGO-63.8%

Dividend Yield (TTM)

ALXON/A

ORGON/A

Rule of 40

ALXO0.0

ORGO11.1

EV/GP/RG

ALXON/A

ORGO0.01

Ticker research

View ALXO research View ORGO research

Metric	ALXO ALX Oncology Holdings Inc	ORGO Organogenesis Holdings Inc
Market & Valuation
Market Cap	$168M	$166M
Enterprise Value	$156M	$132M
Price	$1.25	$1.29
P/E Ratio	N/A	N/A
P/S Ratio	46.09x	0.36x
EV/Sales	0.00x	0.29x
EV/EBITDA	0.00x	7.37x
P/B Ratio	1.24x	0.59x
P/FCF Ratio	N/A	7.96x
EV/FCF	-2.20x	6.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.74x
Revenue & Growth
Revenue (TTM)	$0	$457M
Revenue Growth (YoY)	N/A	6.5%
Forward Rev Growth	357.6%	37.6%
Profitability
Gross Margin (TTM)	9.0%	70.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2.0%
Net Margin (TTM)	0.0%	-23.1%
FCF Margin (TTM)	N/A	4.6%
Net Income (TTM)	$-81M	$-106M
FCF (TTM)	$-71M	$21M
EPS (TTM)	-$0.60	-$0.82
ROE (TTM)	-9030.0%	-2260.0%
ROA (TTM)	-6728.0%	-1654.0%
ROIC (TTM)	-8046.0%	-2187.0%
Financial Health
Cash	$23M	$46M
Debt	$11M	$12M
Net Cash/Debt	$12M	$34M
Current Ratio (TTM)	9.71x	3.52x
Quick Ratio (TTM)	9.44x	2.66x
Debt/Equity (TTM)	0.08x	0.04x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	1.44
52W Performance	-36.5%	-68.8%
YTD Performance	8.7%	-72.2%
% from 52W High	-53.0%	-81.8%
% from 52W Low	19.0%	3.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.90x
FCF Yield (TTM)	-42.2%	12.6%
Earnings Yield (TTM)	-48.1%	-63.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	11.1
EV/GP/RG	N/A	0.01
Ticker research	View ALXO research	View ORGO research

Valuation

P/S Ratio

ORGO

0.36x

ALXO

46.09x

EV/FCF

ALXO

-2.20x

ORGO

6.31x

Growth & revenue

Revenue Growth TTM

ORGO

6.5%

Forward Revenue Growth

ALXO

357.6%

ORGO

37.6%

Profitability & performance

Gross Margin

ORGO

70.4%

ALXO

9.0%

ROE

ORGO

-2260.0%

ALXO

-9030.0%

FCF Yield %

ORGO

12.6%

ALXO

-42.2%

52-Week Performance

ALXO

-36.5%

ORGO

-68.8%

Detailed metrics comparison

ALXO

ALX Oncology Holdings Inc

ORGO

Organogenesis Holdings Inc

Market Cap

ALXO$168M

ORGO$166M

Enterprise Value

ALXO$156M

ORGO$132M

Price

ALXO$1.25

ORGO$1.29

P/E Ratio

ALXON/A

ORGON/A

P/S Ratio

ALXO46.09x

ORGO0.36x

EV/Sales

ALXO0.00x

ORGO0.29x

EV/EBITDA

ALXO0.00x

ORGO7.37x

P/B Ratio

ALXO1.24x

ORGO0.59x

P/FCF Ratio

ALXON/A

ORGO7.96x

EV/FCF

ALXO-2.20x

ORGO6.31x

PEG Ratio

ALXON/A

ORGON/A

Forward P/E (NTM)

ALXON/A

ORGON/A

Forward P/S (NTM)

ALXON/A

ORGO0.74x

Revenue (TTM)

ALXO$0

ORGO$457M

Revenue Growth (YoY)

ALXON/A

ORGO6.5%

Forward Rev Growth

ALXO357.6%

ORGO37.6%

Gross Margin (TTM)

ALXO9.0%

ORGO70.4%

Operating Margin (TTM)

ALXO0.0%

ORGO0.0%

EBITDA Margin (TTM)

ALXO0.0%

ORGO-2.0%

Net Margin (TTM)

ALXO0.0%

ORGO-23.1%

FCF Margin (TTM)

ALXON/A

ORGO4.6%

Net Income (TTM)

ALXO$-81M

ORGO$-106M

FCF (TTM)

ALXO$-71M

ORGO$21M

EPS (TTM)

ALXO-$0.60

ORGO-$0.82

ROE (TTM)

ALXO-9030.0%

ORGO-2260.0%

ROA (TTM)

ALXO-6728.0%

ORGO-1654.0%

ROIC (TTM)

ALXO-8046.0%

ORGO-2187.0%

Cash

ALXO$23M

ORGO$46M

Debt

ALXO$11M

ORGO$12M

Net Cash/Debt

ALXO$12M

ORGO$34M

Current Ratio (TTM)

ALXO9.71x

ORGO3.52x

Quick Ratio (TTM)

ALXO9.44x

ORGO2.66x

Debt/Equity (TTM)

ALXO0.08x

ORGO0.04x

Debt/Assets (TTM)

ALXO0.0%

ORGO0.0%

Interest Coverage (TTM)

ALXON/A

ORGON/A

Net Debt/EBITDA (TTM)

ALXO0.00x

ORGO0.00x

Beta

ALXO0.55

ORGO1.44

52W Performance

ALXO-36.5%

ORGO-68.8%

YTD Performance

ALXO8.7%

ORGO-72.2%

% from 52W High

ALXO-53.0%

ORGO-81.8%

% from 52W Low

ALXO19.0%

ORGO3.2%

Asset Turnover (TTM)

ALXO0.00x

ORGO0.90x

FCF Yield (TTM)

ALXO-42.2%

ORGO12.6%

Earnings Yield (TTM)

ALXO-48.1%

ORGO-63.8%

Dividend Yield (TTM)

ALXON/A

ORGON/A

Rule of 40

ALXO0.0

ORGO11.1

EV/GP/RG

ALXON/A

ORGO0.01

Ticker research

View ALXO research View ORGO research

Metric	ALXO ALX Oncology Holdings Inc	ORGO Organogenesis Holdings Inc
Market & Valuation
Market Cap	$168M	$166M
Enterprise Value	$156M	$132M
Price	$1.25	$1.29
P/E Ratio	N/A	N/A
P/S Ratio	46.09x	0.36x
EV/Sales	0.00x	0.29x
EV/EBITDA	0.00x	7.37x
P/B Ratio	1.24x	0.59x
P/FCF Ratio	N/A	7.96x
EV/FCF	-2.20x	6.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	0.74x
Revenue & Growth
Revenue (TTM)	$0	$457M
Revenue Growth (YoY)	N/A	6.5%
Forward Rev Growth	357.6%	37.6%
Profitability
Gross Margin (TTM)	9.0%	70.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2.0%
Net Margin (TTM)	0.0%	-23.1%
FCF Margin (TTM)	N/A	4.6%
Net Income (TTM)	$-81M	$-106M
FCF (TTM)	$-71M	$21M
EPS (TTM)	-$0.60	-$0.82
ROE (TTM)	-9030.0%	-2260.0%
ROA (TTM)	-6728.0%	-1654.0%
ROIC (TTM)	-8046.0%	-2187.0%
Financial Health
Cash	$23M	$46M
Debt	$11M	$12M
Net Cash/Debt	$12M	$34M
Current Ratio (TTM)	9.71x	3.52x
Quick Ratio (TTM)	9.44x	2.66x
Debt/Equity (TTM)	0.08x	0.04x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.55	1.44
52W Performance	-36.5%	-68.8%
YTD Performance	8.7%	-72.2%
% from 52W High	-53.0%	-81.8%
% from 52W Low	19.0%	3.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.90x
FCF Yield (TTM)	-42.2%	12.6%
Earnings Yield (TTM)	-48.1%	-63.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	11.1
EV/GP/RG	N/A	0.01
Ticker research	View ALXO research	View ORGO research